Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“At the Parker Institute for Cancer Immunotherapy we are developing the next cancer breakthroughs. Ensuring that these therapeutic advances get to patients, faster, is a key goal.
To improve access to potentially life saving clinical trials, new technologies will be part of the answer! AI is poised to assist with feasibility, patient matching, and data collection. Looking forward to discussing on stage at CRAACO2025 with Kent Thoelke and Paradigm Health.”
More posts featuring Karen Knudsen on OncoDaily.
